CytomX Therapeutics (CTMX) Common Equity (2016 - 2025)
Historic Common Equity for CytomX Therapeutics (CTMX) over the last 12 years, with Q3 2025 value amounting to $107.4 million.
- CytomX Therapeutics' Common Equity rose 55790.98% to $107.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $107.4 million, marking a year-over-year increase of 55790.98%. This contributed to the annual value of -$456000.0 for FY2024, which is 9903.89% up from last year.
- Per CytomX Therapeutics' latest filing, its Common Equity stood at $107.4 million for Q3 2025, which was up 55790.98% from $119.9 million recorded in Q2 2025.
- In the past 5 years, CytomX Therapeutics' Common Equity registered a high of $119.9 million during Q2 2025, and its lowest value of -$86.6 million during Q1 2023.
- For the 5-year period, CytomX Therapeutics' Common Equity averaged around -$9.8 million, with its median value being -$29.7 million (2022).
- Per our database at Business Quant, CytomX Therapeutics' Common Equity plummeted by 1858213.51% in 2022 and then surged by 55790.98% in 2025.
- CytomX Therapeutics' Common Equity (Quarter) stood at -$459000.0 in 2021, then crashed by 18582.14% to -$85.8 million in 2022, then surged by 44.67% to -$47.4 million in 2023, then skyrocketed by 99.04% to -$456000.0 in 2024, then soared by 23650.22% to $107.4 million in 2025.
- Its Common Equity was $107.4 million in Q3 2025, compared to $119.9 million in Q2 2025 and $25.0 million in Q1 2025.